Genentech attempts to keep Avastin's breast cancer indication

08/7/2011 | Genetic Engineering & Biotechnology News

In a post-hearing document, Genentech asked the FDA to retain Avastin's breast cancer approval by allowing an updated label as well as a risk evaluation and mitigation strategy and a medication guide. The company also reiterated its plan to undertake a confirmatory study of Avastin plus chemotherapy drug paclitaxel for HER2-negative metastatic breast cancer.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC
Senior Counsel Commercial
RAI Services Company
Winston Salem, NC
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL